• Can changes in EEG improve neuropathic pain treatments - read Oct newsletter.
  • Nine posters ready to reveal at the SfN virtual conference 8-11 Nov, booth 1818.
  • Joined-up preclinical and clinical trials to advance psilocybin drug development
  • Transpharmation joins HaPpY team to help break the vicious cycle of chronic pain & mood disorders, see News for details
  • Announcing new premises in Poland with a focus on neuropsychiatric disorders...
  • New state-of-the-art premises at Discovery Park, Kent


All the latest conference updates; those that we are attending and the studies that we are presenting

Each year ASENT Annual meeting features sessions on emerging therapies in a wide variety of neurologic disease states from Parkinson’s Disease and Movement Disorders, Pain, Multiple Sclerosis, Epilepsy, and a variety of other neurodegenerative Disorders.

Transpharmation will be presenting posters on the topics of “Modulation of the p38 MAPK Pathway in Peripheral Blood Mononuclear Cells (PBMCs): Implications for screening novel anti-inflammatories in Alzheimer’s Disease (AD)” & “Establishment of a reversal learning assay in rats to investigate the effects of novel compounds on executive function.” To get more info on the topics of discussion and registration process please go to https://asent.org/


Start a Conversation

preclinical +44 (0)203 633 2807

clinical trials +353 (0)1896 42 60

clinical research +48 515 244 120

EEG contact@transpharmation.co.uk

Copyright ©2021 Transpharmation Ltd. Website created by Identity Ipswich Web Design